Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...

CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

The pharmaceutical company said late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths worldwide ...

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

Amgen AMGN announced encouraging new data from its interim analysis of the global late-stage study evaluating Imdelltra ...